natgillin/translations-raw huggingface dataset:
Lahko Komisija potrdi, da so ukrepi za odpravo min vključeni v njene nacionalne in regionalne akcijske načrte ter v načrte za zmanjšanje revščine?
Can the Commission reaffirm that its action to eradicate mines is included in its national and regional action plans and poverty reduction plans?
Kakšno prednost se namenja pomoči žrtvam min?
What priority is given to assistance to mine victims?
Kako si Komisija prizadeva za splošno uporabo Ottawske konvencije?
What efforts is the Commission making to universalise the Ottawa Convention?
Kako si Komisija prizadeva premagati "utrujenost donatorjev" in kakšna bo raven finančnih sredstev EU za odstranjevanje min v primerjavi s preteklostjo?
What efforts is the Commission making to overcome 'donor fatigue', and what level of EC mine action financial figures can be counted upon compared to the past?
Kako se lahko zagotovi, da bo odstranjevanje min na prizadetih območjih, ki ga financira Skupnost, vključevalo vse vrste neeksplodiranih bojnih sredstev v prizadetih regijah?
How can it be ensured that in mine-affected areas the clearing of mines financed by the Community does include all types of unexploded ordnance in the affected regions?
Ali Komisija podpira predlog, da novembra 2006, na sedmem srečanju držav podpisnic konvencije o protipehotnih minah v Ženevi, skupaj z EP in predsedstvom EU pripravi vzporedno predstavitev prizadevanj EU za boj proti protipehotnim in protioklepnim minam?
Would the Commission be prepared to organise jointly with the EP and the EU Presidency a parallel event on the EU's efforts to combat anti-personnel and anti-vehicle landmines at the seventh Meeting of States Parties on landmines in November 2006 in Geneva?
USTNO VPRAŠANJE Z RAZPRAVO O-0028/06
ORAL QUESTION WITH DEBATE O-0028/06
Zadeva: Strategija EU proti nevarnosti pandemije influence iz azijskih držav in vloga Svetovne zdravstvene organizacije:
Subject: EU strategy against the risk of an influenza pandemic from Asian countries and the role of the World Health Organisation
Največja nevarnost za pandemijo influence prihaja iz azijskih držav, kjer se virus visoko patogene aviarne influence širi že dve leti, kljub stalnim prizadevanjem pristojnih organov, da bi omejili bolezen.
The greatest risk of an influenza pandemic is from Asian countries, where this highly pathogenic avian influenza virus strain has been spreading for two years, despite continued efforts by competent authorities to contain the disease.
Pandemija zunaj EU bi pomenila tudi resno nevarnost za zdravje državljanov EU.
The occurrence of a pandemic outside the EU would also entail a serious health threat to the citizens of the EU.
Tajvan je edina država na svetu, ki ni vključena v zaščito ZN, če bi epidemija izbruhnila na otoku.
Taiwan is the only country in the world excluded from UN protection if an epidemic breaks out on the island.
Kakšen je namen Sveta glede podpore statusu Tajvana kot opazovalca v Svetovni zdravstveni organizaciji, glede na resolucijo ( P6_TA(2005)0297 ) z dne 7. julija 2005, v kateri Parlament poziva "k večji zastopanosti Tajvana v mednarodnih organizacijah in ponovno poziva Komisijo in države članice k podpori tajvanske vloge za status opazovalca v Svetovni zdravstveni organizaciji", da bi s tem v svetovno strategijo boja proti pandemiji influence povezali vse azijske regionalne partnerje?
With regard to its resolution ( P6_TA(2005)0297 ) adopted on 7 July 2005 in which the Parliament: 'calls for a better representation of Taiwan in international organisations and reiterates its call on the Commission and the Member States to support Taiwan's application for observer status in the WHO', is it the intention of the Council to support Taiwan's observer status in the WHO in order to associate all the Asian regional partners in the World Wide Strategy against an influenza pandemic?
USTNO VPRAŠANJE Z RAZPRAVO O-0029/06
ORAL QUESTION WITH DEBATE O-0029/06
Zadeva: Strategija EU proti nevarnosti pandemije influence iz azijskih držav in vloga Svetovne zdravstvene organizacije
Subject: EU strategy against the risk of an influenza pandemic from Asian countries and the role of the World Health Organisation
Kakšen je namen Komisije glede podpore statusu Tajvana kot opazovalca v Svetovni zdravstveni organizaciji, glede na resolucijo ( P6_TA(2005)0297 ) z dne 7. julija 2005, v kateri Parlament poziva "k večji zastopanosti Tajvana v mednarodnih organizacijah in ponovno poziva Komisijo in države članice k podpori tajvanske vloge za status opazovalca v Svetovni zdravstveni organizaciji", da bi s tem v svetovno strategijo boja proti pandemiji influence povezali vse azijske regionalne partnerje?
With regard to its resolution ( P6_TA(2005)0297 ) adopted on 7 July 2005 in which the Parliament: 'calls for a better representation of Taiwan in international organisations and reiterates its call on the Commission and the Member States to support Taiwan's application for observer status in the WHO', is it the intention of the Commission to support Taiwan's observer status in the WHO in order to associate all the Asian regional partners in the World Wide Strategy against an influenza pandemic?
USTNO VPRAŠANJE Z RAZPRAVO O-0030/06
ORAL QUESTION WITH DEBATE O-0030/06
Zadeva: Financiranje vseevropskega prometnega omrežja (TEN-T)
Subject: Financing trans-European transport networks (TEN-T)
Dovršitev vseevropskega prometnega omrežja je za uresničitev lizbonskih ciljev bistvenega pomena.
The completion of the TEN-T has a vital role in fulfilling the Lisbon targets.
Da bi okrepila svojo konkurenčnost, potrebuje Evropa namesto skupka nepovezanih projektov skladno omrežje.
For increasing its competitiveness Europe needs a coherent network instead of a patchwork of disjointed projects.
Če obljubljeno prometno omrežje ne bo zgrajeno, bodo evropske institucije v očeh evropskih regij in državljanov izgubile verodostojnost.
Should the promised transport network not be delivered, the European institutions would lose their credibility in the eyes of the European regions and citizens.
Svet je v Finančni perspektivi za obdobje 2007-2013 predlagal znesek zgolj 6 milijard evrov, kar je manj kot tretjina zneska, ki ga je predlagal Parlament.
The Council proposed an amount in the FP 2007-2013 of only €6 billion – less than one third of the amount proposed by Parliament.
Zelo očitno je, da predlagani znesek ne zadostuje niti za čezmejne odseke prednostnih projektov.
The Council proposal is clearly not enough even for the cross-border sections of key priority projects.
Za te odseke in z njimi povezano infrastrukturo je potrebnih vsaj 8,175 milijard evrov.
At least €8.175 billion is required for these sections and related infrastructure.
Poleg tega so kratkoročno potrebne še štiri milijarde evrov za druge bistvene vidike prednostnih projektov med njihovo izvedbo.
In addition a further €4 billion is needed in the short term for other vital aspects of priority projects as they become more mature.
Kaj namerava storiti Svet, da bi v naslednjih sedmih letih v proračunu za vseevropsko prometno omrežje zagotovil dovolj sredstev za sofinanciranje vsaj ključnih prednostnih projektov in podporo vsaj najbolj bistvenim vidikom prednostnih projektov?
What measures does the Council intend to take in order to ensure a sufficient amount in the TEN-T budget for co-financing at least the key priority projects in the forthcoming seven years and supporting at least the more vital aspects of other priority projects?
Kaj namerava storiti Svet, da bi bili novi finančni instrumenti, ki jih je sam vzpostavil, na voljo pred koncem leta 2006 in bi v obdobju 2007-2013 stopili v veljavo?
What measures does the Council intend to take in order that the new financial instruments – initiated by the Council – are made available before the end of 2006 in order to become effective in the period 2007-2013?
Kako bo Svet zagotovil znesek vsaj ene milijarde evrov za evropski jamstveni instrument za posojila?
How will the Council ensure at least the amount of €1 billion for the European loan guarantee instrument?
USTNO VPRAŠANJE Z RAZPRAVO O-0031/06
ORAL QUESTION WITH DEBATE O-0031/06
Kaj namerava storiti Komisija, da bi v naslednjih sedmih letih v proračunu za vseevropsko prometno omrežje zagotovila dovolj sredstev za sofinanciranje vsaj ključnih prednostnih projektov in podporo vsaj najbolj bistvenim vidikom prednostnih projektov?
What measures does the Commission intend to take in order to ensure a sufficient amount in the TEN-T budget for co-financing at least the key priority projects in the forthcoming seven years and supporting at least the more vital aspects of other priority projects?
Kaj namerava storiti Komisija, da bi bili novi finančni instrumenti, ki jih je vzpostavil Svet, na voljo pred koncem leta 2006 in bi v obdobju 2007-2013 stopili v veljavo?
What measures does the Commission intend to take in order that the new financial instruments – initiated by the Council – are made available before the end of 2006 in order to become effective in the period 2007-2013?
Kako bo Komisija zagotovila znesek vsaj ene milijarde evrov za evropski jamstveni instrument za posojila?
How will the Commission ensure at least the amount of €1 billion for the European loan guarantee instrument?
USTNO VPRAŠANJE Z RAZPRAVO O-0032/06
ORAL QUESTION WITH DEBATE O-0032/06
Zadeva: Klinično preskušanje TGN1412 v Združenem kraljestvu
Subject: Clinical trials of TGN1412 in the UK
Direktiva 2001/20/ES Evropskega parlamenta in Sveta z dne 4. aprila 2001 (o približevanju zakonov in drugih predpisov držav članic v zvezi z izvajanjem dobre klinične prakse pri kliničnem preskušanju zdravil za ljudi) določa, da so bile države članice obvezane uporabljati določbe direktive z učinkom od 1. maja 2004.
Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 (on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) states that Member States were obliged to apply the provisions of the Directive with effect from 1 May 2004.
Člen 1 direktive pravi, da je „dobra klinična praksa [je] skupek mednarodno priznanih etičnih in znanstvenih zahtev glede kakovosti, ki se morajo spoštovati pri oblikovanju, izvajanju in evidentiranju kliničnih preskušanj ter poročanju o kliničnih preskušanjih, v katerih sodelujejo ljudje.
Article 1 of the Directive says that 'Good clinical practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects.
Skladnost s to dobro prakso zagotavlja, da so pravice, varnost in dobrobit preizkušancev zavarovane in da so rezultati kliničnih preskušanj verodostojni.“
Compliance with this good practice provides assurance that the rights, safety and well-being of trial subjects are protected, and that the results of the clinical trials are credible'.
Iz katastrofalnega sosledja dogodkov na oddelku za preskušanje družbe Parexel v bolnišnici Northwick Park Hospital (London) lahko sklepamo, da klinično preskušanje protivnetnega zdravila TGN1412 na šestih prostovoljcih, ni bilo izpeljano z zadostno previdnostjo.
The catastrophic chain of events which took place in March at the Parexel testing unit at Northwick Park Hospital (London) suggests that the clinical trials of the anti-inflammatory drug TGN1412 on six volunteers cannot have been carried out with sufficient precaution.
Šest moških, starih med 18 in 40 let, je bilo v intenzivni negi še tri dni po njihovi siloviti reakciji na to novo vrsto zdravila: pri štirih se je stanje nekoliko izboljšalo, dva pa ostajata v kritičnem stanju.
The six men, aged 18-40, were all in intensive care still three days after their violent reaction to this new type of drug: four showed some improvements but two remained critically ill.
Med predhodnim preskušanjem na živalih je eden od psov umrl.
During the previous tests on animals one of the dogs had died.
Zdravilo na osnovi protiteles, ki so ga razvijali za zdravljenje levkemije, multiple skleroze in revmatičnega artritisa, proizvaja biofarmacevtsko podjetje Tegenero iz Würzburga v Nemčiji.
The antibody drug which was being developed to treat leukaemia, multiple sclerosis and rheumatoid arthritis is made by Tegenero, a biopharmaceutical company in Würzburg, Germany.
Ali Komisija lahko pove, če so bila ustrezno upoštevana določila Direktive 2001/20/ES?
Can the Commission say if the provisions of Directive 2001/20/EC have been followed correctly?
Zakaj preskušanje ni bilo opravljeno v Nemčiji ali ga tam ni bilo mogoče opraviti?
Why were the tests not or not able to be carried out in Germany?
Je običajna praksa, da se preskušanje izvaja na šestih osebah istočasno in ne postopoma, na eni osebi za drugo, da se zmanjša tveganje?
Is it normal practice for tests to be conducted on six persons simultaneously and not gradually, one after the other, to reduce risk?
Kakšne so nadaljnje smernice, ki jih namerava Komisija pripraviti v luči tega dogodka?
What further guidance will it consider issuing in the light of this incident?
UL L 121, 1.5.2001, str.
OJ L 121, 1.5.2001, p.
USTNO VPRAŠANJE Z RAZPRAVO O-0033/06
ORAL QUESTION WITH DEBATE O-0033/06
Zadeva: Naslednji koraki za obdobje razmisleka
Subject: The next steps for the period of reflection
Kakšni so naslednji koraki, ki jih je Komisija predvidela v zvezi z obdobjem razmisleka o prihodnosti Evrope?
What are the next steps envisaged by the Commission with respect to the period of reflection on the future of Europe?
Kako namerava Komisija izpolniti posebno vlogo, ki so jo zanjo določili voditelji vlad v svoji izjavi z dne 18. junija 2005 s končnim ciljem ratifikacije Pogodbe o Ustavi za Evropo?
How does the Commission intend to fulfil the special role identified for it by the Heads of Government in their Declaration of 18 June 2005 in pursuit of the ratification of the Treaty establishing a Constitution for Europe?
VPRAŠANJE ZA USTNI ODGOVOR Z RAZPRAVO O-0034/06
ORAL QUESTION WITH DEBATE O-0034/06
Zadeva: Pristop Bolgarije in Romunije k Evropski uniji
Subject: Accession of Bulgaria and Romania to the EU
Člen 39 pogodbe o pristopu Bolgarije in Romunije k Evropski uniji določa, da lahko Svet v primeru upravičene bojazni, da bo država očitno nepripravljena na izpolnitev zahtev za članstvo do 1 januarja 2007, za eno leto preloži datum pristopa.
Article 39 of the Treaty of Accession of Bulgaria and Romania to the European Union provides that in the event of a serious risk of a state being manifestly unprepared to meet the requirements of membership by 1 January 2007, the Council may postpone the date of accession by one year.
Takšen korak mora Svetu v razmislek predložiti Komisija.
It is for the Commission to propose such a step for consideration by the Council.
Med plenarno razpravo 12. aprila 2005, ki je potekala, preden je Parlament dal soglasje k pristopni pogodbi, je predsedstvo Sveta potrdilo, da bo stališče Parlamenta o možnem sprejetju zaščitnih ukrepov v celoti upoštevano.
In the plenary debate on 12 April 2005, preceding Parliament's assent to the Treaty of Accession, the Council Presidency confirmed that full account will be taken of Parliament’s position on the possible invoking of safeguard measures.
Predsednik Barroso je v svojem pismu predsedniku Borrellu dne 7. aprila 2005 potrdil, da bo "Komisija resno preučila stališča Parlamenta o možnosti uporabe preložitvene klavzule, preden bi v zvezi s tem izdala kakršnokoli priporočilo, zato da bi bil Evropski parlament polno vključen v morebitno odločitev za preložitev pristopa".
President Barroso confirmed to President Borrell in his letter of 7 April 2005 that 'the Commission would seriously consider the views of the Parliament on the possible use of the postponement clause before issuing any recommendation in this regard, in order to fully associate the European Parliament to any possible decision to postpone accession'.
Ali lahko Komisija, glede na napredek, ki sta ga Bolgarija in Romunija dosegli v izpolnjevanju obveznosti iz pristopne pogodbe, potrdi, da bosta obe državi glede na celotno vsebino, usmeritev in potek njunih reform 31. decembra 2006 pripravljeni na pristop, ne glede na posamezna področja, ki bodo morda zahtevala posebne ukrepe?
In view of the progress made by Bulgaria and Romania towards fulfilling the commitments required by the Treaty of Accession, can the Commission confirm that the overall content, direction, and rhythm of reform in the two countries is such that they will be ready for accession by 31 December 2006, notwithstanding some particular areas of concern which may require special measures?
Se Komisija strinja, da sta zlasti reforma sodstva ter boj proti korupciji in organiziranemu kriminalu področji, ki od Bolgarije in Romunije zahtevata odločnejše prizadevanje in rezultate?
Would the Commission agree that, in particular, the reform of the judiciary and the fight against corruption and organised crime are areas of concern needing more decisive efforts and results from Bulgaria and Romania?
Ali lahko Komisija pojasni možnosti, ki jih ponujajo varnostne klavzule in drugi možni ukrepi, in kaj ti pomenijo v praksi, še zlasti na področju pravosodja in notranjih zadev?
Can the Commission provide a clarification of the possibilities in regard to safeguard clauses and other possible measures and what they mean in practical terms, especially in the area of justice and home affairs?
Ali bi Komisija razmislila o uvedbi 'sistema natančnega spremljanja' za prva tri leta po pristopu, ko bi bilo mogoče uporabiti varnostne klavzule?
Would the Commission consider introducing a 'close monitoring system' throughout the first three years after accession during which safeguard clauses could be invoked?
Ali bi Komisija lahko navedla razloge za pripravo priporočila v maju oziroma jeseni in proti njej:
Could the Commission indicate the pros and cons for making a recommendation respectively in May or in the autumn:
a) glede časovnega okvira pristopa Bolgarije in Romunije in
a) in regard to the timing of accession by Bulgaria and Romania and
b) glede varnostnih klavzul in drugih ukrepov, ki bi bili morda potrebni?
b) in regard to safeguard clauses and any other measures that might possibly be necessary?
VPRAŠANJE ZA USTNI ODGOVOR Z RAZPRAVO O-0035/06/rev.1
ORAL QUESTION WITH DEBATE O-0035/06/rev.1
Zadeva: Izidi zaključka aprilskih srečanj Svetovne trgovinske organizacije (STO) v Ženevi in obeti za prihodnost
Subject: Results of the end of April Geneva meetings of the WTO and future prospects
Ali lahko Svet ovrednoti izide nedavnih srečanj STO v Ženevi, katerih namen je bil doseči sporazum o podrobnih načinih organizacije v kmetijstvu in dostopa do nekmetijskih trgov?
Can the Council evaluate the results of the WTO meetings which recently took place in Geneva to agree on detailed modalities in agriculture and non-agricultural market access?
Ali lahko Svet ovrednoti, kako verjeten je uspešen zaključek razvojnega pogajalskega kroga iz Dohe do konca tega leta, glede na izide srečanj v Ženevi, in ali lahko opiše naslednje korake, ki jih je treba narediti, da se doseže tak izid?
Can the Council provide an evaluation of the likelihood of a successful conclusion of the Doha Development Round by the end of the year in the light of the results of the Geneva meetings and describe the next steps to be taken towards such a conclusion?
Ali lahko Svet predstavi možne usmeritve trgovinske politike EU po morebitnem zaključku razvojnega pogajalskega kroga iz Dohe, tako glede prihodnosti večstranskega trgovinskega sistema kot tudi glede dvostranskih in regionalnih pogajanj?
Can the Council present the possible orientations of the EU trade policy after the eventual conclusion of the Doha Development Round, both in relation to the future of the multilateral trading system and a programme of bilateral and regional negotiations?
VPRAŠANJE ZA USTNI ODGOVOR Z RAZPRAVO O-0036/06/rev.1
ORAL QUESTION WITH DEBATE O-0036/06/rev.1
Ali lahko Komisija ovrednoti izide nedavnih srečanj STO v Ženevi, katerih namen je bil doseči sporazum o podrobnih načinih organizacije v kmetijstvu in dostopa do nekmetijskih trgov?
Can the Commission evaluate the results of the WTO meetings which recently took place in Geneva to agree on detailed modalities in agriculture and non-agricultural market access?
Ali lahko Komisija ovrednoti, kako verjeten je uspešen zaključek razvojnega pogajalskega kroga iz Dohe do konca tega leta, glede na izide srečanj v Ženevi, in ali lahko opiše naslednje korake, ki jih je treba narediti, da se doseže tak izid?
Can the Commission provide an evaluation of the likelihood of a successful conclusion of the Doha Development Round by the end of the year in the light of the results of the Geneva meetings and describe the next steps to be taken towards such a conclusion?
Ali lahko Komisija predstavi možne usmeritve trgovinske politike EU po morebitnem zaključku razvojnega pogajalskega kroga iz Dohe, tako glede prihodnosti večstranskega trgovinskega sistema kot tudi glede dvostranskih in regionalnih pogajanj?
Can the Commission present the possible orientations of the EU trade policy after the eventual conclusion of the Doha Development Round, both in relation to the future of the multilateral trading system and a programme of bilateral and regional negotiations?
VPRAŠANJE ZA USTNI ODGOVOR Z RAZPRAVO O-0037/06
ORAL QUESTION WITH DEBATE O-0037/06
Zadeva: Zaprtje in selitev koncerna Fiat
Subject: Closures and relocations of Fiat operations
Fiatov koncern načrtuje zaprtje enega svojih podjetij v Berlinu (CNH Baumaschinen GmbH), da bi s tem okrepil lastno proizvodno zmogljivost.
The Fiat company is planning to close one of its operations in Berlin (CNH Baumaschinen GmbH) in order to strengthen its own production capacities.
Izven Fiatovega koncerna pa obstajajo interesenti, ki bi radi zadržali lokacijo v Berlinu in s tem ohranili več sto delovnih mest.
Interests other than those of Fiat are calling for the Berlin site to be retained, which would save several hundred jobs.
Vodstvo Fiatovega koncerna teh prizadevanj ne podpira.
These efforts are not receiving the backing of the Fiat management.
Kakšne posledice bo, po mnenju Komisije, imelo zaprtje proizvodnje v Berlinu na regionalni ravni?
What regional implications will the closure of the manufacturing site in Berlin have, in the opinion of the Commission?
Ali so bila evropska sredstva dodeljena neposredno obratu CNH v Berlinu ali selitvi proizvodnih zmogljivosti v Italijo?
Were European funds paid for, or to, the CNH operation in Berlin or in connection with the removal of production capacity to Italy?
Če so, komu in koliko?
If so, to whom were they paid and what were the amounts involved?
Kakšno stališče zastopa Komisija glede ideje/zahteve po uvedbi" dajatve na selitev" t.j. po plačevanju podjetij javnemu sektorju v regiji, kjer prihaja do zapiranja obratov ali znatnega zmanjševanja njihovega števila v prid drugim lokacijam?
What is the Commission’s view of the idea of / call for a ‘relocation levy’, i.e. a payment by the company to the public purse in the region where an operation has been closed down or significantly reduced in size in favour of other sites?
VPRAŠANJE ZA USTNI ODGOVOR Z RAZPRAVO O-0038/06
ORAL QUESTION WITH DEBATE O-0038/06
Zadeva: Ponarejanje zdravil
Subject: Counterfeiting of medicinal products
Ponarejanje zdravil je od vseh ponarejanj najbolj nevarno in nenormalno početje ter predstavlja naraščajoče zlo v številnih državah, kjer ogroža zdravje in celo življenje milijonov ljudi.
The counterfeiting of medicinal products is the most serious and the most amoral of all forms of such deception and it constitutes a growing scourge in many countries, causing the health and even the lives of millions of people to be put at risk.
V obtoku so preveč in premalo dozirana zdravila, zdravila brez aktivnih sestavin in celo strupena zdravila, predvsem v državah v razvoju.
In developing countries in particular, medicinal products are in circulation which are too strong or too weak, have no active ingredient or are even toxic.